Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 354-365

  Diaz Padilla, Ivan ^a,b   Amir, Eitan ^a   Marsh, Sharon ^c   Liu, Geoffrey ^a   MacKay, Helen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b FiHM Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ERCC1; Gene polymorphism; Gynecological cancer; Ovarian cancer; Predictive biomarker; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE; VASCULOTROPIN; VITAMIN D;

APOPTOSIS; COCHRANE LIBRARY; DETOXIFICATION; EMBASE; ENDOMETRIUM CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MEDLINE; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VULVA CANCER; XENOBIOTIC METABOLISM;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856011557     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.10.034     Document Type: Review

References (97)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
2. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
3. D. Pectasides, E. Pectasides, and T. Economopoulos Systemic therapy in metastatic or recurrent endometrial cancer Cancer Treat Rev 33 2007 177 190 (Pubitemid 46343104)
4. D. Pectasides, K. Kamposioras, G. Papaxoinis, and E. Pectasides Chemotherapy for recurrent cervical cancer Cancer Treat Rev 34 2008 603 613
5. X. Zhu, S. Wu, W.L. Dahut, and C.R. Parikh Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2007 186 193 (Pubitemid 46178407)
6. S. Savas, and G. Liu Studying genetic variations in cancer prognosis (and risk): a primer for clinicians Oncologist 14 2009 657 666
7. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
8. A.A. Secord, L.J. Havrilesky, D.M. O'Malley, V. Bae-Jump, N.D. Fleming, and G. Broadwater A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer Gynecol Oncol 114 2009 442 447
9. B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
10. Higgins JPT. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, editor. Cochrane handbook for systematic reviews of interventions version 5.0.0. [updated February 2008]: The Cochrane Collaboration, 2008. Available: http://www.cochrane-handbook.org/.
11. A. Beeghly, D. Katsaros, H. Chen, S. Fracchioli, Y. Zhang, and M. Massobrio Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival Gynecol Oncol 100 2006 330 337 (Pubitemid 43075265)
12. A. Gadducci, C. Di Cristofano, M. Zavaglia, L. Giusti, M. Menicagli, and S. Cosio P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome Anticancer Res 26 2006 687 693 (Pubitemid 43206035)
13. H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin Cancer Res 12 2006 854 859 (Pubitemid 43259868)
14. H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel J Pharm Sci 97 2008 2045 2048
15. M. Heubner, P. Wimberger, K. Riemann, S. Kasimir-Bauer, F. Otterbach, and R. Kimmig The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms Oncol Res 18 2010 343 347
16. S.E. Johnatty, J. Beesley, J. Paul, S. Fereday, A.B. Spurdle, and P.M. Webb ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy Clin Cancer Res 14 2008 5594 5601
17. S. Kang, W. Ju, J.W. Kim, N.H. Park, Y.S. Song, and S.C. Kim Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer Exp Mol Med 38 2006 320 324 (Pubitemid 44033245)
18. A.V. Khrunin, A. Moisseev, V. Gorbunova, and S. Limborska Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients Pharmacogenomics J 10 2010 54 61
19. H.S. Kim, M.K. Kim, H.H. Chung, J.W. Kim, N.H. Park, and Y.S. Song Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study Gynecol Oncol 113 2009 264 269
20. T.C. Krivak, K.M. Darcy, C. Tian, D. Armstrong, B.E. Baysal, and H. Gallion Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer J Clin Oncol 26 2008 3598 3606
21. T.C. Krivak, K.M. Darcy, C. Tian, M. Bookman, H. Gallion, and C.B. Ambrosone Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study Gynecol Oncol 122 2011 121 126
22. S. Marsh, J. Paul, C.R. King, G. Gifford, H.L. McLeod, and R. Brown Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J Clin Oncol 25 2007 4528 4535 (Pubitemid 350035308)
23. E.C. Morari, A.B. Lima, N.E. Bufalo, J.L. Leite, F. Granja, and L.S. Ward Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients J Cancer Res Clin Oncol 132 2006 521 528 (Pubitemid 43938336)
24. C.M. Nagle, G. Chenevix-Trench, A.B. Spurdle, and P.M. Webb The role of glutathione-S-transferase polymorphisms in ovarian cancer survival Eur J Cancer 43 2007 283 290 (Pubitemid 46123985)
25. H. Obata, T. Yahata, J. Quan, M. Sekine, and K. Tanaka Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer Anticancer Res 26 2006 2227 2232 (Pubitemid 43980177)
26. J.S. Saldivar, K.H. Lu, D. Liang, J. Gu, M. Huang, and A.T. Vlastos Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients Gynecol Oncol 107 2007 S223 S229
27. S. Smith, and D. Su Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J Clin Oncol 25 2007 5172 5179 (Pubitemid 350232247)
28. K.D. Steffensen, M. Waldstrom, U. Jeppesen, I. Brandslund, and A. Jakobsen Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 2008 702 710 (Pubitemid 352020157)
29. M. Takano, M. Kato, T. Yoshikawa, N. Sasaki, J. Hirata, and K. Furuya Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study Oncology 76 2009 315 321
30. U.A. Germann P-glycoprotein-a mediator of multidrug resistance in tumour cells Eur J Cancer 32A 1996 927 944
31. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, and A. Johne Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478 (Pubitemid 30183327)
32. M.M. Baekelandt, R. Holm, J.M. Nesland, C.G. Trope, and G.B. Kristensen P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res 20 2000 1061 1067 (Pubitemid 30240677)
33. J.J. Yu, K.B. Lee, C. Mu, Q. Li, T.V. Abernathy, and F. Bostick-Bruton Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene Int J Oncol 16 2000 555 560
34. M. Quintela-Fandino, R. Hitt, P.P. Medina, S. Gamarra, L. Manso, and H. Cortes-Funes DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy J Clin Oncol 24 2006 4333 4339 (Pubitemid 46630792)
35. W. Zhou, S. Gurubhagavatula, G. Liu, S. Park, D.S. Neuberg, and J.C. Wain Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin Cancer Res 10 2004 4939 4943 (Pubitemid 39099767)
36. R.C. Strange, M.A. Spiteri, S. Ramachandran, and A.A. Fryer Glutathione-S-transferase family of enzymes Mutat Res 482 2001 21 26 (Pubitemid 32787078)
37. C.C. McIlwain, D.M. Townsend, and K.D. Tew Glutathione S-transferase polymorphisms: cancer incidence and therapy Oncogene 25 2006 1639 1648
38. J. Batra, O.L. Tan, T. O'Mara, R. Zammit, C.M. Nagle, and J.A. Clements Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival Int J Gynecol Cancer 20 2010 529 536
39. V. Galic, J. Willner, M. Wollan, R. Garg, R. Garcia, and B.A. Goff Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas Genes Chromosomes Cancer 46 2007 239 247 (Pubitemid 46155319)
40. C. Grimm, S. Polterauer, R. Zeillinger, C. Tempfer, G. Sliutz, and A. Reinthaller The prohibitin 3′ untranslated region polymorphism in patients with ovarian cancer Eur J Obstet Gynecol Reprod Biol 137 2008 236 239 (Pubitemid 351423456)
41. C. Grimm, S. Polterauer, R. Zeillinger, D. Tong, G. Heinze, and A. Wolf Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer Anticancer Res 30 2010 3487 3491
42. E. Ioana Braicu, A. Mustea, M.R. Toliat, C. Pirvulescu, D. Konsgen, and P. Sun Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients Gynecol Oncol 104 2007 680 685 (Pubitemid 46240260)
43. A. Mann, E. Hogdall, S.J. Ramus, R.A. DiCioccio, C. Hogdall, and L. Quaye Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients Eur J Cancer 44 2008 2259 2265
44. H. Song, E. Hogdall, S.J. Ramus, R.A. Dicioccio, C. Hogdall, and L. Quaye Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival Clin Cancer Res 14 2008 1090 1095 (Pubitemid 351302555)
45. F. Bartel, J. Jung, A. Bohnke, E. Gradhand, K. Zeng, and C. Thomssen Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival Clin Cancer Res 14 2008 89 96 (Pubitemid 351377982)
46. J. Batra, C.M. Nagle, T. O'Mara, M. Higgins, Y. Dong, and O.L. Tan A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival BMC Cancer 11 2011 119
47. R. Garg, M. Wollan, V. Galic, R. Garcia, B.A. Goff, and H.J. Gray Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma Gynecol Oncol 103 2006 793 796 (Pubitemid 44821354)
48. E.L. Goode, M.J. Maurer, T.A. Sellers, C.M. Phelan, K.R. Kalli, and B.L. Fridley Inherited determinants of ovarian cancer survival Clin Cancer Res 16 2010 995 1007
49. C.H. Han, Y.J. Huang, K.H. Lu, Z. Liu, G.B. Mills, and Q. Wei Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer J Exp Clin Cancer Res 30 2011 5
50. L.A. Hefler, C. Grimm, S. Ackermann, S. Malur, A.R. Radjabi-Rahat, and S. Leodolter An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer Cancer Res 63 2003 3066 3068 (Pubitemid 36735853)
51. T. Higashi, S. Kyo, M. Inoue, H. Tanii, and K. Saijoh Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer J Mol Diagn 8 2006 342 350 (Pubitemid 44063811)
52. A.J. Li, R.L. Baldwin, and B.Y. Karlan Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma Clin Cancer Res 9 2003 3667 3673 (Pubitemid 37169233)
53. D. Liang, L. Meyer, D.W. Chang, J. Lin, X. Pu, and Y. Ye Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response Cancer Res 70 2010 9765 9776
54. A.H. Ludwig, M. Murawska, G. Panek, A. Timorek, and J. Kupryjanczyk Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome Endocr Relat Cancer 16 2009 1005 1016
55. C.M. Nagle, G. Chenevix-Trench, P.M. Webb, and A.B. Spurdle Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes Cancer Lett 251 2007 96 104 (Pubitemid 46589770)
56. A.J. Paige, M. Zucknick, S. Janczar, J. Paul, C.A. Mein, and K.J. Taylor WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis Eur J Cancer 46 2010 818 825
57. L. Quaye, S.A. Gayther, S.J. Ramus, R.A. Di Cioccio, V. McGuire, and E. Hogdall The effects of common genetic variants in oncogenes on ovarian cancer survival Clin Cancer Res 14 2008 5833 5839
58. A.M. Santos, H. Sousa, C. Portela, D. Pereira, D. Pinto, and R. Catarino TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer Biochem Biophys Res Commun 340 2006 256 262 (Pubitemid 41827674)
59. A.M. Schultheis, G. Lurje, K.E. Rhodes, W. Zhang, D. Yang, and A.A. Garcia Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin Cancer Res 14 2008 7554 7563
60. L. Six, C. Grimm, S. Leodolter, C. Tempfer, R. Zeillinger, and G. Sliutz A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer Gynecol Oncol 100 2006 506 510 (Pubitemid 43246866)
61. S. Tamez, C. Norizoe, K. Ochiai, D. Takahashi, A. Shimojima, and Y. Tsutsumi Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer Br J Cancer 101 2009 1957 1960
62. J. Wynendaele, A. Bohnke, E. Leucci, S.J. Nielsen, I. Lambertz, and S. Hammer An illegitimate microRNA target site within the 3′UTR of MDM4 affects ovarian cancer progression and chemosensitivity Cancer Res 70 2010 9641 9649
63. A. Reles, W.H. Wen, A. Schmider, C. Gee, I.B. Runnebaum, and U. Kilian Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 7 2001 2984 2997 (Pubitemid 32963815)
64. E.C. Pietsch, O. Humbey, and M.E. Murphy Polymorphisms in the p53 pathway Oncogene 25 2006 1602 1611
65. G.L. Bond, W. Hu, and A.J. Levine MDM2 is a central node in the p53 pathway: 12 years and counting Curr Cancer Drug Targets 5 2005 3 8 (Pubitemid 40321795)
66. N. Dijsselbloem, S. Goriely, V. Albarani, S. Gerlo, S. Francoz, and J.C. Marine A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to Genistein J Immunol 178 2007 5048 5057 (Pubitemid 46595288)
67. M. Phelps, M. Darley, J.N. Primrose, and J.P. Blaydes p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells Cancer Res 63 2003 2616 2623 (Pubitemid 36605204)
68. H.A. Risch Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone J Natl Cancer Inst 90 1998 1774 1786 (Pubitemid 28559889)
69. A. Evangelou, S.K. Jindal, T.J. Brown, and M. Letarte Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells Cancer Res 60 2000 929 935 (Pubitemid 30129528)
70. M.R. Cardillo, E. Petrangeli, N. Aliotta, L. Salvatori, L. Ravenna, and C. Chang Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study J Exp Clin Cancer Res 17 1998 231 237 (Pubitemid 28335584)
71. G. Buchanan, M. Yang, A. Cheong, J.M. Harris, R.A. Irvine, and P.F. Lambert Structural and functional consequences of glutamine tract variation in the androgen receptor Hum Mol Genet 13 2004 1677 1692 (Pubitemid 39173438)
72. L.A. Hefler, A. Mustea, D. Konsgen, N. Concin, B. Tanner, and R. Strick Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer Clin Cancer Res 13 2007 898 901 (Pubitemid 46340365)
73. F. Lose, C.M. Nagle, T. O'Mara, J. Batra, K.L. Bolton, and H. Song Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival Gynecol Oncol 119 2010 479 483
74. S. Polterauer, C. Grimm, A. Mustea, N. Concin, B. Tanner, and F. Thiel Vascular endothelial growth factor gene polymorphisms in ovarian cancer Gynecol Oncol 105 2007 385 389 (Pubitemid 46613900)
75. M.P. Smerdel, K.D. Steffensen, M. Waldstrom, I. Brandslund, and A. Jakobsen The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab Gynecol Oncol 118 2010 167 171
76. M.P. Smerdel, M. Waldstrom, I. Brandslund, K.D. Steffensen, R.F. Andersen, and A. Jakobsen Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer Int J Gynecol Cancer 19 2009 578 584
77. K.D. Steffensen, M. Waldstrom, I. Brandslund, and A. Jakobsen The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer Gynecol Oncol 117 2010 109 116
78. M. Amano, S. Yoshida, S. Kennedy, N. Takemura, M. Deguchi, and N. Ohara Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population Eur J Gynaecol Oncol 29 2008 333 337
79. X.D. Cheng, W.G. Lu, F. Ye, X.Y. Wan, and X. Xie The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma J Exp Clin Cancer Res 28 2009 91
80. H.H. Chung, M.K. Kim, J.W. Kim, N.H. Park, Y.S. Song, and S.B. Kang XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer Gynecol Oncol 103 2006 1031 1037 (Pubitemid 44821330)
81. K. Einarsdottir, H. Darabi, K. Czene, Y. Li, Y.L. Low, and Y.Q. Li Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival Br J Cancer 100 2009 1358 1364
82. K. Kim, S.B. Kang, H.H. Chung, J.W. Kim, N.H. Park, and Y.S. Song XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer Gynecol Oncol 111 2008 509 515
83. Y.H. Kim, M.A. Kim, I.A. Park, W.Y. Park, J.W. Kim, and S.C. Kim VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival Gynecol Oncol 119 2010 232 236
84. Y.H. Kim, I.A. Park, W.Y. Park, J.W. Kim, S.C. Kim, and N.H. Park Hypoxia-inducible factor 1alpha polymorphisms and early-stage cervical cancer Int J Gynecol Cancer 21 2011 2 7
85. E. Lerma, M. Romero, A. Gallardo, C. Pons, J. Munoz, and J. Fuentes Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma Virchows Arch 452 2008 65 74
86. A.M. Mehta, E.S. Jordanova, W.E. Corver, T. van Wezel, H.W. Uh, and G.G. Kenter Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma Genes Chromosomes Cancer 48 2009 410 418
87. E.K. Riener, L.A. Hefler, C. Grimm, A. Galid, R. Zeillinger, and D. Tong-Cacsire Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer Gynecol Oncol 93 2004 686 690 (Pubitemid 38766056)
88. G. Rodriguez, C. Bilbao, R. Ramirez, O. Falcon, L. Leon, and R. Chirino Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer Int J Cancer 118 2006 1420 1425
89. Y.H. Kim, I.-A. Park, W.-Y. Park, J.W. Kim, S.C. Kim, and N.-H. Park Hypoxia-inducible factor 1 polymorphisms and early-stage cervical cancer Int J Gynecol Cancer 21 2011 2 7
90. D.P. Cronin-Fenton, and T.L. Lash Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes Expert Rev Clin Pharmacol 4 2011 363 377
91. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184 (Pubitemid 41258223)
92. J.A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I.B. Vergote, and G.J.S. Rustin Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) J Clin Oncol 29 2011 (suppl; abstr 5003)
93. M.J. Birrer, P. Konstantinopoulos, R.T. Penson, M. Roche, A. Ambrosio, and T.E. Stallings A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer J Clin Oncol 29 2011 (suppl; abstr 5005)
94. R.T. Penson, C. Whalen, B. Lasonde, C.N. Krasner, P. Konstantinopoulos, and T.E. Stallings A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer J Clin Oncol 29 2011 (suppl; abstr 5004)
95. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study J Clin Oncol 28 18s 2010 (suppl; abstr LBA1)
96. G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J.A. Ledermann, and F. Joly Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer J Clin Oncol 29 2011 (suppl; abstr LBA5006)
97. C. Aghajanian, N.J. Finkler, T. Rutherford, D.A. Smith, J. Yi, and H. Parmar OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) J Clin Oncol 29 2011 (suppl; abstr LBA5007)